Table 2. Association of clinical outcomes with microRNA-181a expression in 187 patients with CN-AML <60 years old (22).
Outcome | Higher expression | Lower expression | P |
---|---|---|---|
Compete remission | 84% | 72% | 0.07 |
5-year Disease-free survival | 43% | 18% | 0.05 |
5-year Survival | 48% | 19% | 0.01 |
For descriptive purposes, the percentages are reported for patients dichotomized at the median, but miR-181a expression was analyzed statistically as a continuous variable.